Cryptococcus neoformans kills 180,000 people per year, mostly immunocompromised patients. Echinocandins — the most important class of antifungal drugs — cannot touch it. The fungal cell membrane resists the drug's entry. Building a new antifungal that can penetrate the membrane while avoiding toxicity to human cells is extraordinarily difficult because fungal cells and human cells share most of the same membrane biology. Every drug that kills the fungus tends to damage the patient.
Chen, Wright, and colleagues at McMaster University (Cell, 2025) took eleven years to find a different answer. In 2014, they screened thousands of compounds from a chemical library. Butyrolactol A — a small molecule produced by Streptomyces bacteria, known for decades but largely ignored — showed no antifungal activity on its own. It cannot kill Cryptococcus. It cannot even slow its growth.
What it can do is inhibit Apt1-Cdc50, a phospholipid flippase in the fungal cell membrane. Flippases maintain membrane asymmetry — the unequal distribution of lipid species between the inner and outer leaflets of the bilayer. This asymmetry is load-bearing. It organizes vesicular trafficking, maintains cytoskeletal attachment, and creates the permeability barrier that excludes drugs. When butyrolactol A jams the flippase, the membrane loses its organized structure. The lipids scramble. The barrier thins. And echinocandins — which the fungus had been resisting — walk through.
The molecule is an adjuvant, not a drug. It does not kill the pathogen. It strips the pathogen's defense so that an existing drug, previously useless, becomes lethal. The combination of butyrolactol A plus caspofungin kills Cryptococcus. Neither compound alone does anything. The killing requires both: one to disarm, one to strike.
The same approach works against Candida auris, a different resistant fungal species with the same flippase machinery. The target is conserved; the vulnerability is general.
The structural insight is about the search strategy. For decades, antifungal drug discovery has looked for molecules that kill fungi. The screening metric was minimum inhibitory concentration — the lowest dose that stops growth. Butyrolactol A would score zero on that metric. It has no antifungal activity. It would be — and was, for decades — discarded as inactive.
The McMaster team spent eleven years validating a molecule that fails every standard drug screen. The compound's value is invisible to the metric that defines the field. The measurement — “does this molecule kill the pathogen?” — excludes the entire category of molecules whose function is to make other molecules effective. The adjuvant strategy is not a refinement of the killing strategy. It is a different kind of answer to the same problem, one that the standard assay is structurally incapable of finding.